Sara Lugmayr

Sara Lugmayr

Auto-generated profile, based on publicly available information

Sara Lugmayr

Department of Pathophysiology and Clinical Research Institute for Cardiovascular and Metabolic Disease, Faculty of Medicine, Johannes Kepler University

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2026 in Expert Reviews in Molecular Medicine
Verified
Journal Article
Open access
SLSara Lugmayr
Sara Lugmayr
EHElisabeth Heuböck
Elisabeth Heuböck
DBDavid Bernhard
David Bernhard
MMMarkus Mandl
Markus Mandl
VCVerena Charwat
Verena Charwat
Background: Myocardial infarction (MI) remains a critical focus in cardiovascular research, with in vitro models serving as essential tools for investigating pathophysiological mechanisms and evaluating therapeutic strategies. Despite their widespread use, the clinical relevance of these models is often assumed rather than rigorously validated. Methods: In this review, we systematically examined 28 studies from the last decade that employed in vitro co-culture models of MI, selected via a PubMed search according to pre-defined criteria. Each study was analysed with respect to ischaemia/reperfusion (I/R)-mimicking conditions applied, species and cell types used, and strategies for verifying clinical relevance. Results: Our analysis revealed considerable heterogeneity in experimental design. Protocols for inducing I/R stress and the duration of treatment varied widely between studies, underscoring a lack of methodological standardization. Cell sources included swine, rat, mouse and human-derived cells, with nearly half of the studies utilizing cross-species combinations – often without addressing the implications for translational validity. Verification strategies were inconsistently applied and frequently limited to basic endpoints such as cell viability and oxidative stress assays. Some studies also employed in vivo models to validate in vitro findings. Conclusions: To enhance translational potential, future studies should prioritize human-derived cells, standardized I/R protocols and verification strategies that better recapitulate MI pathology.